Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
10/28/2022* -- Results Q3 2022 -- -2.46 --
10/28/2022* 08:30 EST Earnings Call Q3 2022 -- -- --
08/02/2022 -- Results Q2 2022 -2.68 -2.26 -18.42%
08/02/2022 08:00 EST Earnings Call Q2 2022 -- -- --
05/03/2022 -- Results Q1 2022 -1.79 -1.85 3.15%
05/03/2022 08:30 EST Earnings Call Q1 2022 -- -- --
02/16/2022 -- Results Q4 2021 -5.40 -1.57 -243.7%
02/16/2022 08:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 10/28/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/02/2022
Beat/Miss Upgrade
Return Since 11.62%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
URL https://www.blueprintmedicines.com
Investor Relations URL https://ir.blueprintmedicines.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Oct. 28, 2022 (est.)
Last Earnings Release Aug. 02, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
6.49%
168.8%
-28.51%
48.60%
40.00%
-4.49%
-41.34%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-20.46%
166.6%
-28.90%
102.8%
96.14%
18.24%
32.12%
-47.18%
27.51%
--
--
--
15.00%
-70.65%
-72.96%
-28.90%
-53.50%
--
--
-66.88%
-57.90%
24.74%
76.67%
16.04%
-61.30%
42.88%
8.94%
17.72%
45.37%
75.39%
107.2%
38.20%
-17.54%
As of October 06, 2022.

Profile

Edit
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
URL https://www.blueprintmedicines.com
Investor Relations URL https://ir.blueprintmedicines.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Oct. 28, 2022 (est.)
Last Earnings Release Aug. 02, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
IDNA 8.163M USD 4.74%
XDNA.TO 182833.0 USD 3.68%
FBTTX 54.28M USD 3.32%
BBP 335725.0 USD 2.03%
FBIOX 85.31M USD 1.69%
ETCHX 22.15M USD 1.68%
FTXH 472160.0 USD 1.27%
F000016CO1 122.00 USD 1.22%
FPHAX 7.996M USD 0.91%
PNASX 20.82M USD 0.91%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter BPMC Tweets